Teprotumumab Treatment in Patients With Active Thyroid Eye Disease

NCT ID: NCT01868997


Title
A Multicenter, Double-masked, Placebo-controlled, Efficacy and Safety Study of an Insulin-like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), in Patients With Active Thyroid Eye Disease
Purpose
The purpose of this study is to evaluate the safety, tolerability and effectiveness of a fully human antibody compared to placebo in the treatment of patients with active thyroid eye disease. "Funding Source - FDA OOPD"
Details
A multicenter, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (TED)
Conditions
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Keywords
Thyroid Eye Disease, Graves Orbitopathy, Thyroid Associated, Ophthalmopathy
Source
River Vision Development Corporation
Sponsors
River Vision Development Corporation
Status
Active, not recruiting
Acronym
Last Updated
22 Nov 2016
URL
Official Link
Locations
Germany, Italy, United Kingdom, United States